Journal of Reports in Pharmaceutical Sciences

ORIGINAL ARTICLE
Year
: 2020  |  Volume : 9  |  Issue : 1  |  Page : 68--72

Evaluation of cytotoxic and apoptotic effects of DT386–BR2: A promising anticancer fusion protein


Fatemeh Shafiee, Mohammad Rabbani, Ali Jahanian-Najafabadi 
 Department of Pharmaceutical Biotechnology, School of Pharmacy and Pharmaceutical Sciences, Isfahan University of Medical Sciences, Isfahan, Iran

Correspondence Address:
Dr. Ali Jahanian-Najafabadi
Department of Pharmaceutical Biotechnology, School of Pharmacy and Pharmaceutical Sciences, Isfahan University of Medical Sciences, Hezar Jarib Ave., Isfahan.
Iran

Purpose: In the previous studies, we designed an anticancer immunotoxin containing the catalytic and translocation domains of diphtheria toxin fused to BR2, a buforin II-derived antimicrobial peptide as a cancer-specific cell penetrating peptide, in order to target various cancer cells. The aim of this study was to evaluate the in vitro cytotoxicity of DT386–BR2 against K-562 cells as the most famous cell line for leukemia. Materials and Methods: MTT and flow-cytometry assays were used for determining the cytotoxic effects and cell death mechanism of DT386–BR2, respectively, against K-562 cell line. The recombinant DT386 and synthetic BR2 were used as the negative control in cytotoxicity assay. Results: The results of this study showed a significant reduction in survival of K-562 cells caused by DT386–BR2 as compared with BR2 and DT386 fragments. On the contrary, the flow-cytometry results showed apoptosis induction by DT386–BR2 after 12h in a dose- and time-dependent manner. Conclusion: DT386–BR2 fusion protein can be used for further preclinical studies for determining its pharmacokinetic/pharmacodynamic profiles and evaluating its anticancer efficacy in suitable animal models.


How to cite this article:
Shafiee F, Rabbani M, Jahanian-Najafabadi A. Evaluation of cytotoxic and apoptotic effects of DT386–BR2: A promising anticancer fusion protein.J Rep Pharma Sci 2020;9:68-72


How to cite this URL:
Shafiee F, Rabbani M, Jahanian-Najafabadi A. Evaluation of cytotoxic and apoptotic effects of DT386–BR2: A promising anticancer fusion protein. J Rep Pharma Sci [serial online] 2020 [cited 2020 Oct 27 ];9:68-72
Available from: https://www.jrpsjournal.com/article.asp?issn=2322-1232;year=2020;volume=9;issue=1;spage=68;epage=72;aulast=Shafiee;type=0